Wedbush raised the firm’s price target on Vor Bio (VOR) to $15 from $9 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and started patient dosing in Phase 3 UPSTREAM SjD – telitacicept for Sjogren’s disease. Wedbushs speculates a trial timeline of about three years based on precedent from ianalumab in NEPTUNUS-1 and NEPTUNUS-2.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio price target lowered to $40 from $55 at Stifel
- Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
- Vor Bio doses first patient in UPSTREAM SjD study
- Vor Bio initiated with a Buy at Jefferies
- Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating